Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Fully equipped labs with 75-member team set-up and made operational in <100 days
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Subscribe To Our Newsletter & Stay Updated